PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
This report contains market size and forecasts of PARP (Poly ADP-ribose Polymerase) Inhibitors in Global, including the following market information:
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global PARP (Poly ADP-ribose Polymerase) Inhibitors market was valued at 2943.8 million in 2021 and is projected to reach US$ 19900 million by 2028, at a CAGR of 31.4% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Olaparib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of PARP (Poly ADP-ribose Polymerase) Inhibitors include AbbVie, Pfizer, AstraZeneca, GlaxoSmithKline, Clovis Oncology and Everest Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the PARP (Poly ADP-ribose Polymerase) Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Segment Percentages, by Type, 2021 (%)
Olaparib
Talazoparib
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Segment Percentages, by Application, 2021 (%)
Ovarian Cancer
Breast Cancer
Other
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies PARP (Poly ADP-ribose Polymerase) Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies PARP (Poly ADP-ribose Polymerase) Inhibitors revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals